The DOI matches its Crossref record; 60 of the 60 references it cites were found in a registry or an index.
Transcriptional Activation by p53 of the Human Type IV Collagenase (Gelatinase A or Matrix Metalloproteinase 2) Promoter
Open accessAbstract
p53, a tumor suppressor and a transcription factor, has been shown to transcriptionally activate the expression of a number of important genes involved in the regulation of cell growth, DNA damage, angiogenesis, and apoptosis. In a computer search for other potential p53 target genes, we identified a perfect p53 binding site in the promoter of the human type IV collagenase (also called 72-kDa gelatinase or matrix metalloproteinase 2 [MMP-2]) gene. This p53 binding site was found to specifically bind to p53 protein in a gel shift assay. Transcription assays with luciferase reporters driven by the promoter or enhancer of the type IV collagenase gene revealed that (i) activation of the promoter activity is p53 binding site dependent in p53-positive cells but not in p53-negative cells and (ii) wild-type p53, but not p53 mutants commonly found in human cancers, transactivates luciferase expression driven by the type IV collagenase promoter as well as by a p53 site-containing enhancer element in the promoter. Significantly, expression of the endogenous type IV collagenase is also under the control of p53. Treatment of U2-OS cells, a wild-type p53-containing osteogenic sarcoma line, with a common p53 inducer, etoposide, induced p53 DNA binding and transactivation activities in a time-dependent manner. Induction of type IV collagenase expression followed the p53 activation pattern. No induction of type IV collagenase expression can be detected under the same experimental conditions in p53-negative Saos-2 cells. All these in vitro and in vivo assays strongly suggest that the type IV collagenase gene is a p53 target gene and that its expression is subject to p53 regulation. Our finding links p53 to a member of the MMP genes, a family of genes implicated in trophoblast implantation, wound healing, angiogenesis, arthritis, and tumor cell invasion. p53 may regulate these processes by upregulating expression of type IV collagenase.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
WAF1, a potential mediator of p53 tumor suppression
El-Deiry, W. S., Tokino, T., Velculescu, V. E., Levy, D. B., Parsons, R., Trent, J. M., Lin, D., Mercer, W. E., Kinzler, K. W., & Vogelstein, B. (1993) · Cell · doi:10.1016/0092-8674(93)90500-p · Cited by 8,321
p53 Mutations in Human Cancers
Hollstein, M., Sidransky, D., Vogelstein, B., & Harris, C. C. (1991) · Science · doi:10.1126/science.1905840 · Cited by 8,018
Tumor suppressor p53 is a direct transcriptional activator of the human bax gene
Toshiyuki, M., & Reed, J. C. (1995) · Cell · doi:10.1016/0092-8674(95)90412-3 · Cited by 4,063 · cited 2×
“Among the commonly studied genes in this group are those for Waf1/Cip1/p21 (11), Mdm2 (1), Gadd45 (22), Bax (30), proliferating cell nuclear antigen (32, 39), cyclin G (36), epidermal growth factor receptor (29), and thrombospondin (7).”
BackgroundParticipation of p53 protein in the cellular response to DNA damage.
Kastan, M. B., Onyekwere, O. C., Sidransky, D., Vogelstein, B., & Craig, R. W. (1991) · PubMed · Cited by 3,761
Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis.
Greenblatt, M. S., Bennett, W. P., Hollstein, M., & Harris, C. C. (1994) · PubMed · Cited by 3,463
Matrix metalloproteinases and their inhibitors in connective tissue remodeling
Woessner, J. F. (1991) · The FASEB Journal · doi:10.1096/fasebj.5.8.1850705 · Cited by 3,282
Kastan, M. B., Zhan, Q., El-Deiry, W. S., Carrier, F., Jacks, T., Walsh, W. V., Plunkett, B. S., Vogelstein, B., & Fornace, A. J. (1992) · Cell · doi:10.1016/0092-8674(92)90593-2 · Cited by 3,047
Matrix Metalloproteinases: A Review
Birkedal-Hansen, H., Moore, W. G. I., Bodden, M. K., Windsor, L. J., Birkedal-Hansen, B., DeCarlo, A., & Engler, J. A. (1993) · Critical Reviews in Oral Biology & Medicine · doi:10.1177/10454411930040020401 · Cited by 2,970
Cancer metastasis and angiogenesis: An imbalance of positive and negative regulation
Liotta, L. A., Steeg, P. S., & Stetler-Stevenson, W. G. (1991) · Cell · doi:10.1016/0092-8674(91)90642-c · Cited by 2,720
Ko, L. J., & Prives, C. (1996) · Genes & Development · doi:10.1101/gad.10.9.1054 · Cited by 2,344
Cited by
How Matrix Metalloproteinases Regulate Cell Behavior
Sternlicht, M. D., & Werb, Z. (2001) · Annual Review of Cell and Developmental Biology · doi:10.1146/annurev.cellbio.17.1.463 · Cited by 3,959
“In addition, a functional p53-binding site has been identified in the MMP2 gene promoter (Bian & Sun 1997), and wild-type p53 downregulates basal and inducible MMP1 gene expression in human fibroblasts and osteogenic sarcoma cells, whereas some mutant forms do not (Sun et al. 1999).”
BackgroundTumorigenesis and the angiogenic switch
Bergers, G., & Benjamin, L. E. (2003) · Nature reviews. Cancer · doi:10.1038/nrc1093 · Cited by 3,559
Live or let die: the cell's response to p53
Vousden, K. H., & Lu, X. (2002) · Nature Reviews Cancer · doi:10.1038/nrc864 · Cited by 3,192
Transcriptional control of human p53-regulated genes
Riley, T., Sontag, E., Chen, P., & Levine, A. (2008) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2395 · Cited by 1,921
A Matter of Life and Cell Death
Evan, G., & Littlewood, T. (1998) · Science · doi:10.1126/science.281.5381.1317 · Cited by 1,523
The regulation of matrix metalloproteinases and their inhibitors
Clark, I. M., Swingler, T. E., Sampieri, C. L., & Edwards, D. R. (2008) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2007.12.006 · Cited by 555
ECM signalling: orchestrating cell behaviour and misbehaviour
Lukashev, M. (1998) · Trends in Cell Biology · doi:10.1016/s0962-8924(98)01362-2 · Cited by 550
Xie, T.-X., Wei, D., Liu, M., Gao, A. C., Ali-Osman, F., Sawaya, R., & Huang, S. (2004) · Oncogene · doi:10.1038/sj.onc.1207383 · Cited by 550
Matrix Metalloproteinases Increase Very Early during Experimental Focal Cerebral Ischemia
Heo, J. H., Lucero, J., Abumiya, T., Koziol, J. A., Copeland, B. R., & del Zoppo, G. J. (1999) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1097/00004647-199906000-00005 · Cited by 547
Curran, S., & Murray, G. I. (2000) · European Journal of Cancer · doi:10.1016/s0959-8049(00)00156-8 · Cited by 531
The role of gelatinases in colorectal cancer progression and metastasis
Mook, O. R. F., Frederiks, W. M., & Van Noorden, C. J. F. (2004) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2004.09.006 · Cited by 511
The role of apoptosis in wound healing
Greenhalgh, D. G. (1998) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/s1357-2725(98)00058-2 · Cited by 494
Identification of Novel, Functional Genetic Variants in the Human Matrix Metalloproteinase-2 Gene
Price, S. J., Greaves, D. R., & Watkins, H. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m010242200 · Cited by 406
Kenny, H. A., Kaur, S., Coussens, L. M., & Lengyel, E. (2008) · Journal of Clinical Investigation · doi:10.1172/jci33775 · Cited by 370
Contribution of p53 to Metastasis
Powell, E., Piwnica-Worms, D., & Piwnica-Worms, H. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0136 · Cited by 355
The possible role of matrix metalloproteinase (MMP)-2 and MMP-9 in cancer, e.g. acute leukemia
Klein, G., Vellenga, E., Fraaije, M. W., Kamps, W. A., & de Bont, E. S. J. M. (2004) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2003.09.001 · Cited by 350
Piccoli, M.-T., Gupta, S. K., Viereck, J., Foinquinos, A., Samolovac, S., Kramer, F. L., Garg, A., Remke, J., Zimmer, K., Batkai, S., et al. (2017) · Circulation Research · doi:10.1161/circresaha.117.310624 · Cited by 344
Qin, H., Sun, Y., & Benveniste, E. N. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.41.29130 · Cited by 271
Self-citationInhibition of tumor angiogenesis by p53: a new role for the guardian of the genome
Teodoro, J. G., Evans, S. K., & Green, M. R. (2007) · Journal of Molecular Medicine · doi:10.1007/s00109-007-0221-2 · Cited by 260
Transcriptional Activation of the Human Glutathione Peroxidase Promoter by p53
Tan, M., Li, S., Swaroop, M., Guan, K., Oberley, L. W., & Sun, Y. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.17.12061 · Cited by 253
Self-citationTan, M., Wang, Y., Guan, K., & Sun, Y. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.1.109 · Cited by 252
Self-citationThe transcription factor p53: Not a repressor, solely an activator.
Fischer, M., Steiner, L., & Engeland, K. (2014) · Cell Cycle · doi:10.4161/15384101.2014.949083 · Cited by 153
Recent developments in the regulation of the angiogenic switch by cellular stress factors in tumors
North, S., Moenner, M., & Bikfalvi, A. (2005) · Cancer Letters · doi:10.1016/j.canlet.2004.08.007 · Cited by 113
Chintala, H., Liu, H., Parmar, R., Kamalska, M., Kim, Y. J., Lovett, D., Grant, M. B., & Chaqour, B. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.386565 · Cited by 43
Metadata
- Authors
- Bian, J., & Sun, Y.
- Venue
- Molecular and Cellular Biology
- Publisher
- Informa UK Limited
- Published
- 1997-11
- Volume
- 17
- Issue
- 11
- Pages
- 6330-6338
- ISSN
- 0270-7306 (ISSN-L)
- 1098-5549
- OpenAlex
- W2122374538
- Cited by
- 276
- References
- 60
- FWCI
- 4.30
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.